The primary objective of this trial is to determine the optimal dose and imaging time point(s) of I-124-CLR1404 in subjects with newly diagnosed and recurrent glioma to be used in future trials.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
7
single-dose, intravenous
City of Hope
Duarte, California, United States
Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
University of Maryland School of Medicine
Baltimore, Maryland, United States
Cleveland Clinic
Optimal Imaging Parameters - Dose
Up to two dose levels (5 mCi and 7.5 mCi) will be evaluated in conjunction with multiple imaging time points to determine the optimal parameters for PET/CT brain imaging. Dosing will begin at 5 mCi and if the images are deemed inadequate, as assessed by count statistics and image quality, the 7.5 mCi dose level will be evaluated.
Time frame: 8 days
Optimal Imaging Parameters - Imaging Time Point
Multiple imaging time points (Day 2, Day 3, and Day 4-8) will be evaluated to determine the optimal parameters for PET/CT brain imaging.
Time frame: 8 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Cleveland, Ohio, United States
Ohio State University Medical Center
Columbus, Ohio, United States
Kettering Medical Center
Kettering, Ohio, United States
Hospital of University of Pennsylvania
Philadelphia, Pennsylvania, United States
University of Wisconsin
Madison, Wisconsin, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States